 |
인쇄하기
취소
|
KFDA approves Vimpat as adjunct antiepileptic drug
The Korea Food and Drug Administration said on August 6 it has approved UCB's Vimpat (lacosamide) for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain.
Vimpat is an orally-available anticonvulsant. It selectively enhances slow inactivation of sodium channels and interacts with the neuroplasticity-relevant target -collapsin-response mediator protein-2 (CRMP-2)....
Vimpat is an orally-available anticonvulsant. It selectively enhances slow inactivation of sodium channels and interacts with the neuroplasticity-relevant target -collapsin-response mediator protein-2 (CRMP-2)....
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.